We use cookies to analyze site traffic and improve your experience.
By accepting, you consent to the use of analytics cookies.

SPCE:NYSEVirgin Galactic Holdings, Inc. Analysis

Data as of 2026-05-02 - not real-time

$2.65

Latest Price

8/10Risk

Risk Level: High

Executive Summary

Virgin Galactic’s stock is trading around $2.65, just above the 20‑day SMA (2.80) but still below the 200‑day SMA (3.25), suggesting a short‑term tilt that lacks long‑term momentum. The 14‑day RSI sits near 50, the MACD line is negative and the signal is bearish, and volume is on a decreasing trend, all pointing to a neutral‑to‑bearish technical backdrop. However, the share price remains comfortably above the computed support level of $2.27 and well below the resistance at $3.32, while the 30‑day volatility is extreme at roughly 97% and beta approaches 2, indicating that price swings can be severe.
On the fundamentals side, the company posted a narrower Q4 loss ($0.98 EPS versus $1.04 expected) and cut operating expenses by 25%, signaling improving cost discipline. Strategic growth plans—including upcoming spacecraft test flights—are highlighted in the earnings call, but cash of $307 M is still outpaced by $375 M of debt, and profitability metrics (negative EPS, PE, and operating margin) remain poor. No dividend is paid, and the forward PE is deeply negative, underscoring the high‑risk, high‑reward nature of the investment.

Market Outlook

Short Term

< 1 year
Neutral
Model confidence: 6/10

Key Factors

  • Bearish MACD and decreasing volume
  • Extreme short‑term volatility and high beta
  • Price near support with limited upside to resistance

Medium Term

1–3 years
Positive
Model confidence: 7/10

Key Factors

  • Narrowing losses and 25% expense reduction
  • Strategic growth pipeline of commercial flights
  • Undervalued price relative to book value

Long Term

> 3 years
Positive
Model confidence: 8/10

Key Factors

  • Long‑term tailwinds in space tourism and aerospace
  • Potential for revenue upside as fleet becomes operational
  • Current market price offers a discount to intrinsic asset value

Key Metrics & Analysis

Financial Health

Revenue Growth-27.30%
P/E Ratio-7.4
ROE-93.55%
ROA-20.21%
Debt/Equity136.99
P/B Ratio0.7
Op. Cash Flow$-240142000
Free Cash Flow$-339664128
Industry P/E31.2

Technical Analysis

TrendNeutral
RSI49.5
Support$2.27
Resistance$3.32
MA 20$2.80
MA 50$2.61
MA 200$3.25
MACDBearish
VolumeDecreasing
Fear & Greed Index91.09

Valuation

Target Price$3.61
Upside/Downside36.23%
GradeUndervalued
TypeValue

Risk Assessment

Beta1.97
Volatility97.40%
Sector RiskMedium
Reg. RiskMedium
Geo RiskLow
Currency RiskLow
Liquidity RiskMedium

This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.